Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (CRVO) is a clinical-stage biotechnology company pioneering treatments for neurodegenerative disorders, including dementia with Lewy bodies (DLB). This page serves as the definitive source for official company announcements, research breakthroughs, and clinical development milestones.
Investors and researchers will find timely updates on CervoMed's lead drug candidate neflamapimod, a p38MAPK inhibitor targeting synaptic dysfunction. The curated news collection includes press releases on clinical trial progress, regulatory filings, scientific presentations, and strategic partnerships.
Key updates cover Phase 2b trial developments, biomarker validation studies, and expert analyses of neurodegenerative disease mechanisms. All content is sourced directly from CervoMed's communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to CervoMed's latest advancements in neurotherapeutics. Regularly updated to reflect new developments, this resource supports informed decision-making for stakeholders tracking innovative neurological treatments.
CervoMed (NASDAQ: CRVO) reported Phase 2b RewinD-LB results on Oct 8, 2025 showing neflamapimod activity in dementia with Lewy bodies (DLB).
In participants with plasma ptau181 <21 pg/mL (low likelihood of Alzheimer’s co-pathology), NFMD/B produced significant within-subject improvement on CDR-SB versus placebo (difference = −1.12, p=0.005) and improved clinical scales during the first 16 weeks of the Extension Phase. NFMD/B reduced risk of clinically meaningful progression by 67% versus NFMD/A over 32 weeks and 75% versus placebo over 16 weeks (both p<0.001).
Plasma GFAP fell with NFMD/B (median −16.7 pg/mL vs +5.8 pg/mL on placebo; median difference −23.1 pg/mL, p=0.016), and GFAP change correlated with CDR-SB change (p=0.036). The company expects FDA feedback on Phase 3 design in Q4 2025.
CervoMed (NASDAQ: CRVO) appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer on Oct 7, 2025 to strengthen commercialization and corporate growth as the company advances into late‑stage Phase 3 development for neflamapimod in dementia with Lewy bodies (DLB). Dr. Winton brings nearly two decades of CNS commercial experience, including leadership roles at Biogen and Inozyme and involvement in a recent acquisition. CervoMed granted an inducement option for 75,000 shares at an exercise price of $8.62 on Oct 6, 2025 that vests monthly over three years commencing Oct 31, 2025.
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference in New York, NY.
Company management will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" on Thursday, October 9, 2025, at 8:00 AM ET. The company will also be available for one-on-one meetings with institutional investors during the conference.
CervoMed (NASDAQ: CRVO) highlighted its drug neflamapimod's potential benefits for treating Dementia with Lewy Bodies (DLB) at the 150th Annual American Neurological Association conference. The presentation showcased promising Phase 2b trial results, which demonstrated a significant 74% risk reduction in disease progression compared to placebo in patients with low likelihood of concurrent Alzheimer's Disease pathology.
The company is preparing to initiate a Phase 3 trial for DLB patients and expects to finalize the trial design with the FDA in Q4 2025. The presentation was delivered by Dr. James Galvin, Professor of Neurology and Co-Principal Investigator of the RewinD-LB study.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, from 2:00 to 2:30 PM ET, with both presentation and one-on-one investor meetings. Additionally, CervoMed will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, 2025, featuring one-on-one investor meetings.
CervoMed (NASDAQ: CRVO) reported Q2 2025 financial results and provided updates on its Phase 2b RewinD-LB trial for neflamapimod in Dementia with Lewy Bodies (DLB). The 32-week Extension phase data showed a 54% risk reduction in clinical worsening, improving to 64% in patients with minimal Alzheimer's co-pathology.
The company reported $33.5 million in cash and equivalents as of June 30, 2025, with funding runway into Q3 2026. Q2 2025 financial results showed grant revenue of $1.8 million, R&D expenses of $5.1 million, and a net loss of $6.3 million. CervoMed plans to engage with FDA in Q4 2025 to discuss Phase 3 trial design, with trial initiation targeted for mid-2026.
The company also enrolled first patients in Phase 2a trials for acute stroke recovery and frontotemporal dementia.CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 12, 2025, at 2:00 PM ET.
The presentation will be available via webcast, accessible through the company's investor relations website. During the conference, which runs from August 12-14, 2025, management will also conduct one-on-one meetings with investors.
CervoMed (NASDAQ: CRVO) announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial for neflamapimod in treating Dementia with Lewy Bodies (DLB). The trial demonstrated a 54% risk reduction in clinically significant worsening compared to control, improving to 64% in patients with minimal Alzheimer's Disease co-pathology.
Key findings include a significant reduction in plasma levels of glial fibrillary acidic protein (GFAP) at week 32, and improved efficacy with new capsules achieving target plasma concentrations. The study showed a 40% lower rate of clinically meaningful worsening in patients receiving new capsules versus old capsules, with both formulations maintaining similar safety profiles.
CervoMed plans to meet with the FDA in Q4 2025 to discuss Phase 3 trial design for this potential treatment of the second most common form of dementia.
CervoMed (NASDAQ: CRVO), a clinical stage company focused on neurologic disorder treatments, will present new data from its Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies (DLB) at AAIC 2025.
The company will host a conference call on July 28, 2025, at 8:00 AM ET to discuss primary endpoint results at 32-weeks from the Extension phase. Investors can access the webcast through the company's website, with domestic participants dialing 1-877-425-9470 and international participants dialing 1-201-389-0878 using code 13755139.
CervoMed (NASDAQ: CRVO), a clinical stage company specializing in age-related neurologic disorders, will present late-breaking research at the Alzheimer's Association® International Congress (AAIC) 2025 in Toronto from July 27-31, 2025.
The company will showcase results from their RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) through two presentations: an in-person poster discussing effects on clinical progression in DLB patients without Alzheimer's disease co-pathology, and a virtual presentation examining the impact of AD co-pathology on treatment response.
FAQ
What is the current stock price of CervoMed (CRVO)?
What is the market cap of CervoMed (CRVO)?
